BenevolentAI
Philip Clarke is a seasoned professional in the field of drug metabolism and pharmacokinetics (DMPK), currently serving as Senior Principal Scientist at BenevolentAI since November 2018, where scientific and management leadership is provided to the DMPK group. Prior experience includes significant roles at Vertex Pharmaceuticals, Evotec, Prosidion, Pfizer, and Quintiles, with responsibilities ranging from leading bioanalytical activities to managing large teams and developing innovative biomarker strategies. Philip holds a PhD in Analytical Chemistry from Sheffield Hallam University and a BSc in Chemistry from the University of Plymouth, bringing extensive expertise in bioanalysis and DMPK to various research and development projects across the pharmaceutical industry.
This person is not in any teams
This person is not in any offices
BenevolentAI
8 followers
BenevolentAI combines advanced AI and machine learning with cutting edge science to decipher complex disease biology, generate novel insights and discover more effective medicines. Our unique computational R&D platform spans every step of the drug discovery process, powering an in-house pipeline of 25+ drug programmes from early discovery towards clinical phases. With several successful collaborations with leading pharmaceutical organisations, we are also the only AI-drug discovery company with a clinically validated approach, discovering a leading repurposed drug candidate for COVID-19. BenevolentAI is headquartered in London with a research facility in Cambridge (UK) and a further office in New York, with a team of over 300 world-leading scientists and technologists progressing its mission to reinvent drug discovery and advance life-changing drugs through to the clinic.